

Primary tumor site	Number of patients	%
1) Oral cavity	3111	26.9
2) Nasal cavity, etc.	643	5.6
3) Nasopharynx	323	2.8
4) Oropharynx	2082	18.0
5) Hypopharynx	2566	22.2
6) Larynx	2157	18.7
7) Major salivary glands	667	5.8
8) Primary Unknown	14	0.1
Total	11563	100

Nasal cavity, etc.: nasal cavity and paranasal sinuses

	MFT to relapse (month; range)	MFT to death or last follow-up (month)	Death or last follow-up	in 2018	in 2019	in 2020	in 2021	in 2022	after 2023
1) Oral cavity	31.04 (0.03-98.03)	56.1		193(19.2%)	322(32.0%)	180(17.9%)	91(9.1%)	66(6.6%)	153(15.2%)
2) Nasal cavity, etc.	13.99 (0.03-95.37)	39.2		53(20.5%)	79(30.6%)	44(17.1%)	22(8.5%)	24(9.3%)	36(14.0%)
3) Nasopharynx	38.14 (0.03-92.28)	62.5		18(18.0%)	18(18.0%)	20(20.0%)	8(8.0%)	15(15.0%)	21(21.0%)
4) Oropharynx	32.89 (0.03-93.96)	59.0		115(17.6%)	190(29.1%)	103(15.8%)	82(12.6)	54(8.3%)	108(16.6%)
5) Hypopharynx	22.19 (0.03-93.23)	49.0		176(16.9%)	294(28.3%)	195(18.8%)	115(11.1%)	91(8.8%)	169(16.3%)
6) Larynx	44.42 (0.03-91.33)	59.1		63(11.5%)	124(22.5%)	110(20.0%)	75(13.6%)	58(10.6%)	120(21.8%)
7) Major salivary glands	21.94 (0.03-90.47)	50.8		37(17.8%)	64(30.8%)	35(16.8%)	25(12.0%)	17(8.2%)	30(14.4%)
8) Primary Unknown	20.5 (1.74-78.35)	31.5		1(16.7%)	3(50.0%)	1(16.7%)	1(16.7%)	0(0%)	0(0%)

Nasal cavity, etc.: nasal cavity and paranasal sinuses

*Abbreviation: MFT; Median follow-up time.

	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands	8) Primary Unknown						
Relapse lesion	Number of Patients (Number of DOD)													
No	1998 (39)	304 (8)	209 (8)	1396 (45)	1542 (60)	1665 (30)	385 (16)	8 (1)						
Local	279 (123)	110 (50)	30 (15)	173 (64)	228 (85)	150 (38)	27 (12)	0 (0)						
Regional	335 (126)	31 (13)	10 (4)	127 (40)	188 (92)	88 (40)	38 (13)	2 (1)						
Distant	158 (109)	56 (31)	46 (23)	129 (68)	265 (148)	104 (52)	141 (54)	3 (0)						
Local+Regional	47 (29)	10 (7)	3 (1)	34 (21)	28 (18)	15 (12)	2 (0)	0 (0)						
Local+Distant	17 (13)	16 (11)	2 (1)	18 (11)	11 (8)	6 (4)	6 (5)	0 (0)						
Regional+Distant	29 (22)	6 (2)	1 (1)	18 (12)	52 (44)	19 (10)	8 (6)	1 (1)						
Local+Regional+Distant	12 (10)	4 (2)	0 (0)	8 (6)	12 (6)	4 (1)	7 (3)	0 (0)						
Undecidable	180 (125)	93 (55)	17 (14)	151 (83)	206 (137)	75 (39)	42 (22)	0 (0)						
Unknown	56 (1)	13 (1)	5 (0)	28 (3)	34 (9)	31 (2)	11 (0)	0 (0)						
Total	3111 (597)	643 (180)	323 (67)	2082 (353)	2566 (607)	2157 (228)	667 (131)	14 (3)						

Nasal cavity, etc.: nasal cavity and paranasal sinuses

*Abbreviation: DOD; Death of Disease.

	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands	8) Primary Unknown
Disease stage	Median follow-up time to death or last follow-up (month)							
0	62.4	61.6	-	69.1	69.2	62.9	-	-
1	61.9	70.8	66.8	63.6	64.0	61.3	65.4	70.3
2	59.9	68.6	64.7	59.9	59.1	61.5	65.0	-
3	44.9	45.8	65.3	51.3	46.6	57.3	60.2	28.9
4a	33.9	36.1	44.7	30.5	37.5	37.5	36.7	1.7
4b	15.7	19.2	60.4	28.3	21.3	22.2	16.7	25.5
4c	10.2	11.1	58.1	10.5	9.3	10.0	11.7	-
Unknown	59.8	51.1	43.8	57.9	50.5	43.4	61.8	50.7

Nasal cavity, etc.: nasal cavity and paranasal sinuses

Number of metachronous multiple cancer by primary tumor site (pre- / post-primary cancer)

	<u>No</u>	<u>Head and Neck</u>	<u>Esophagus</u>	<u>Lung</u>	<u>Stomach</u>	<u>Liver</u>	<u>Colon</u>	<u>Others</u>	<u>Unknown</u>	<u>No reported</u>
1) Oral cavity	1489/1524	161/99	73/51	24/46	54/24	6/5	32/20	69/55	11/21	1275/1297
2) Nasal cavity, etc.	340/345	8/0	0/3	5/5	7/1	1/2	7/4	8/7	1/6	268/271
3) Nasopharynx	176/163	2/4	0/2	1/1	1/1	1/0	1/4	1/6	0/1	141/143
4) Oropharynx	987/1019	114/92	124/58	18/36	40/24	8/10	26/12	48/54	5/13	800/809
5) Hypopharynx	999/1062	87/122	270/162	40/54	92/29	12/13	34/21	81/68	9/16	1063/1087
6) Larynx	1097/1046	19/43	43/33	35/57	46/37	11/13	36/20	58/60	9/15	834/852
7) Major salivary glands	361/371	7/1	3/1	3/12	5/1	2/3	8/4	19/16	3/4	259/259
8) Primary Unknown	6/7	0/0	0/0	1/0	0/0	0/0	0/0	0/0	0/0	7/7

Nasal cavity, etc.: nasal cavity and paranasal sinuses

Number of clinical outcome by primary tumor site

	Survival (%)	Death of primary cancer (%)	Death of other cancer (%)	Death of other disease (%)	Death of unknown cause (%)	Unknown (%)	total (%)
1) Oral cavity	2106 (67.7)	597 (19.2)	77 (2.5)	111 (3.6)	27 (0.9)	193 (6.2)	3111 (100)
2) Nasal cavity, etc.	385 (59.9)	180 (28.0)	4 (0.6)	12 (1.9)	10 (1.6)	52 (8.1)	643 (100)
3) Nasopharynx	223 (69.0)	67 (20.7)	8 (2.5)	6 (1.9)	5 (1.5)	14 (4.3)	323 (100)
4) Oropharynx	1430 (68.7)	353 (17.0)	54 (2.6)	82 (3.9)	35 (1.7)	128 (6.1)	2082 (100)
5) Hypopharynx	1526 (59.5)	607 (23.7)	112 (4.4)	138 (5.4)	45 (1.8)	138 (5.4)	2566 (100)
6) Larynx	1607 (74.5)	228 (10.6)	75 (3.5)	84 (3.9)	30 (1.4)	133 (6.2)	2157 (100)
7) Major salivary glands	459 (68.8)	131 (19.6)	8 (1.2)	15 (2.2)	6 (0.9)	48 (7.2)	667 (100)
8) Primary Unknown	8 (57.1)	3 (21.4)	1 (7.1)	0 (0.0)	0 (0.0)	2 (###)	14 (100)

Nasal cavity, etc.: nasal cavity and paranasal sinuses